Ole Bitsch-Jensen
Directeur/Membre du Conseil chez Asiros A/S
Profil
Ole Bitsch-Jensen is currently a Director at Asiros A.
He previously served as Chairman at 2cureX ApS, Helion Biotech ApS, FluimediX ApS, and Minervax ApS.
He was also a Director at Ranger Biotechnologies A, CytoTrack ApS, Pharma 2100 ApS, and OncoNOx ApS.
Additionally, he worked as an Investment Manager at SEED Capital Management I from 2001 to 2013.
Mr. Bitsch-Jensen received his undergraduate degree from Copenhagen Business School and his graduate degree from the Technical University of Denmark.
Postes actifs de Ole Bitsch-Jensen
| Sociétés | Poste | Début |
|---|---|---|
Asiros A/S
 Asiros A/S Agricultural Commodities/MillingProcess Industries Asiros A/S manufactures bioactive based food ingredients and formulation. Its products include BerryShield berry powders used to manufacture berry powders and MitoActive products are based on the discovery of a bioactive compound in certain varieties of red- and blackcurrants. The comapny was founded in 2007 and is headquartered in Copenhagen, Denmark. | Directeur/Membre du Conseil | - |
Anciens postes connus de Ole Bitsch-Jensen
| Sociétés | Poste | Fin |
|---|---|---|
Valderm ApS
 Valderm ApS Pharmaceuticals: MajorHealth Technology Valderm ApS is focused on the development of the second generation anthracycline valrubicin for innovative once daily topical treatment of hyper proliferative skin diseases e.g. psoriasis. Preclinical studies have confirmed the anti-proliferative effect of valrubicin and an attractive safety profile upon repeated topical applications has been documented. The company was founded in 2003 and is headquartered in Lyngby, Denmark. | Directeur/Membre du Conseil | 21/05/2014 |
SEED Capital Management I/S
 SEED Capital Management I/S Investment ManagersFinance SEED Capital Management I/S is an Independent Venture Capital firm founded in 2004. The company is headquartered in Copenhagen, Denmark. | Private Equity Investor | 30/04/2013 |
Helion Biotech ApS
 Helion Biotech ApS Pharmaceuticals: MajorHealth Technology Helion Biotech ApS develops and manufactures drugs. It develops a recombinant human protein from the innate immune system (MASP-2) for therapeutic use in cancer. The firm's MASP-2 protein is used to prevent or treat infectious episodes in MASP-2 deficient patients undergoing chemotherapy. The company was founded by Jeppe Vesti Christensen, Per Bo Pedersen Fischer, Jens Christian Jensenius and Steffen Thiel in 2008 and is headquartered in Lyngby, Denmark. | Président | 01/03/2010 |
OncoNOx ApS
 OncoNOx ApS Pharmaceuticals: MajorHealth Technology OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark. | Directeur/Membre du Conseil | - |
Pharma 2100 ApS
 Pharma 2100 ApS Pharmaceuticals: MajorHealth Technology Pharma 2100 ApS engages in the research and development of pharmaceutical products. It conducts research on medical drugs to obtain patents and possible productions of these drugs. The company was founded on January 1, 2002 and is headquartered in Vanløse, Denmark. | Directeur/Membre du Conseil | - |
Formation de Ole Bitsch-Jensen
| Copenhagen Business School | Undergraduate Degree |
| Technical University of Denmark | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
SEED Capital Management I/S
SEED Capital Management I/S Investment ManagersFinance SEED Capital Management I/S is an Independent Venture Capital firm founded in 2004. The company is headquartered in Copenhagen, Denmark. | Finance |
Valderm ApS
Valderm ApS Pharmaceuticals: MajorHealth Technology Valderm ApS is focused on the development of the second generation anthracycline valrubicin for innovative once daily topical treatment of hyper proliferative skin diseases e.g. psoriasis. Preclinical studies have confirmed the anti-proliferative effect of valrubicin and an attractive safety profile upon repeated topical applications has been documented. The company was founded in 2003 and is headquartered in Lyngby, Denmark. | Health Technology |
2cureX ApS
 2cureX ApS Pharmaceuticals: MajorHealth Technology 2cureX ApS develops and manufactures drugs and technology for the treatment of cancer. Its ChemoCellomics, integrates synthesis of compound libraries with throughput screening (HTS) in primary cells from patients. The company was founded by Ole Thastrup, Timm Jessen, and Grith Hagel in 2006 and is headquartered in Birkerod, Denmark. | Health Technology |
Helion Biotech ApS
Helion Biotech ApS Pharmaceuticals: MajorHealth Technology Helion Biotech ApS develops and manufactures drugs. It develops a recombinant human protein from the innate immune system (MASP-2) for therapeutic use in cancer. The firm's MASP-2 protein is used to prevent or treat infectious episodes in MASP-2 deficient patients undergoing chemotherapy. The company was founded by Jeppe Vesti Christensen, Per Bo Pedersen Fischer, Jens Christian Jensenius and Steffen Thiel in 2008 and is headquartered in Lyngby, Denmark. | Health Technology |
Ranger Biotechnologies A/S
 Ranger Biotechnologies A/S Miscellaneous Commercial ServicesCommercial Services Mirrx Therapeutics A/S provides protein production technology. Its technology Blockmirs, is steric antisense blockers that bind to specific microRNA binding sites in target RNAs to thereby prevent microRNA binding to the same site. The company was founded by Hans Thorleif Møller on July 1, 2009 and is headquartered in Vejle, Denmark. | Commercial Services |
CytoTrack ApS
 CytoTrack ApS Electronic Equipment/InstrumentsElectronic Technology CytoTrack ApS engages in the provision of medical scanners for rare cell detection systems. Its products include CytoTrack CT11 scanner, CytoDisk and CytoCover, and CytoTrack reagent kit. The company was founded by Christian Caspersen, Tom Hede Markussen and Lars Ulrik Nielsen in 2004 and is headquartered in Lyngby, Denmark. | Electronic Technology |
FluimediX ApS
 FluimediX ApS Medical SpecialtiesHealth Technology FluimediX ApS provides diagnostic system capable of deoxyribonucleic acid based species determination. Its product, called NanoCycler, delivers an identification of the presence of patogen species, based on their unique DNA 'fingerprint'. The firm markets its product for the use of the dairy production industry. It also collaborates with others in the fields of engineering, microtechnology, and surface analysis. The company was founded by Tomas Ussing in 2003 and is headquartered in Taastrup, Denmark. | Health Technology |
Pharma 2100 ApS
Pharma 2100 ApS Pharmaceuticals: MajorHealth Technology Pharma 2100 ApS engages in the research and development of pharmaceutical products. It conducts research on medical drugs to obtain patents and possible productions of these drugs. The company was founded on January 1, 2002 and is headquartered in Vanløse, Denmark. | Health Technology |
Minervax ApS
 Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Health Technology |
OncoNOx ApS
OncoNOx ApS Pharmaceuticals: MajorHealth Technology OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |
Asiros A/S
Asiros A/S Agricultural Commodities/MillingProcess Industries Asiros A/S manufactures bioactive based food ingredients and formulation. Its products include BerryShield berry powders used to manufacture berry powders and MitoActive products are based on the discovery of a bioactive compound in certain varieties of red- and blackcurrants. The comapny was founded in 2007 and is headquartered in Copenhagen, Denmark. | Process Industries |
